Literature DB >> 33510935

"Neuroacanthocytosis" - Overdue for a Taxonomic Update.

Ruth H Walker1, Adrian Danek2.   

Abstract

The term "neuroacanthocytosis" (NA) is used for a spectrum of neurological disorders in which there are thorny red blood cells. While NA historically referred to disorders of lipoprotein absorption, we have promoted it as an overarching term for a group of basal ganglia disorders, with specific reference to two diseases that we defined as "core" NA syndromes. "Neuroacanthocytosis" has also been used to refer to a specific, now genetically-defined disease, otherwise known as "chorea-acanthocytosis". These various usages have resulted in diagnostic confusion, and in a number of cases have quite likely prevented the pursuance of precise, molecular, diagnosis. Disease nomenclature is an ever-evolving field, especially in the current era of expanding genetics, and naming proposals are often far from ideal. We, however, suggest that the term "neuroacanthocytosis" should no longer be generally used and if so, only with appropriate understanding of its limitations. Further, we propose that chorea-acanthocytosis be renamed as "VPS13A disease" in accordance with its genetic etiology. Copyright:
© 2021 The Author(s).

Entities:  

Keywords:  McLeod syndrome; VPS13A; acanthocytosis; chorea-acanthocytosis; neuroacanthocytosis

Mesh:

Year:  2021        PMID: 33510935      PMCID: PMC7805383          DOI: 10.5334/tohm.583

Source DB:  PubMed          Journal:  Tremor Other Hyperkinet Mov (N Y)        ISSN: 2160-8288


  31 in total

1.  A new phenotype (McLeod) in the Kell blood-group system.

Authors:  F H ALLEN; S M KRABBE; P A CORCORAN
Journal:  Vox Sang       Date:  1961-09       Impact factor: 2.144

2.  Extending the aceruloplasminemia phenotype: NBIA on imaging and acanthocytosis, yet only minor neurological findings.

Authors:  Rebecca Kassubek; Ingo Uttner; Carlos Schönfeldt-Lecuona; Jan Kassubek; Bernhard J Connemann
Journal:  J Neurol Sci       Date:  2017-03-16       Impact factor: 3.181

3.  Chorea-acanthocytosis without chorea: Expanding the clinical phenotype.

Authors:  Silvio Peluso; Leonilda Bilo; Marcello Esposito; Antonella Antenora; Anna De Rosa; Sabina Pappatà; Giuseppe De Michele
Journal:  Parkinsonism Relat Disord       Date:  2017-05-17       Impact factor: 4.891

Review 4.  Molecular Basis and Clinical Overview of McLeod Syndrome Compared With Other Neuroacanthocytosis Syndromes: A Review.

Authors:  Eileen Roulis; Catherine Hyland; Robert Flower; Christoph Gassner; Hans H Jung; Beat M Frey
Journal:  JAMA Neurol       Date:  2018-12-01       Impact factor: 18.302

5.  GLUT1 mutations are a cause of paroxysmal exertion-induced dyskinesias and induce hemolytic anemia by a cation leak.

Authors:  Yvonne G Weber; Alexander Storch; Thomas V Wuttke; Knut Brockmann; Judith Kempfle; Snezana Maljevic; Lucia Margari; Christoph Kamm; Susanne A Schneider; Stephan M Huber; Arnulf Pekrun; Robert Roebling; Guiscard Seebohm; Saisudha Koka; Camelia Lang; Eduard Kraft; Dragica Blazevic; Alberto Salvo-Vargas; Michael Fauler; Felix M Mottaghy; Alexander Münchau; Mark J Edwards; Anna Presicci; Francesco Margari; Thomas Gasser; Florian Lang; Kailash P Bhatia; Frank Lehmann-Horn; Holger Lerche
Journal:  J Clin Invest       Date:  2008-06       Impact factor: 14.808

6.  Compound heterozygous PANK2 mutations confirm HARP and Hallervorden-Spatz syndromes are allelic.

Authors:  H Houlden; S Lincoln; M Farrer; P G Cleland; J Hardy; R W Orrell
Journal:  Neurology       Date:  2003-11-25       Impact factor: 9.910

Review 7.  Nomenclature of genetic movement disorders: Recommendations of the international Parkinson and movement disorder society task force.

Authors:  Connie Marras; Anthony Lang; Bart P van de Warrenburg; Carolyn M Sue; Sarah J Tabrizi; Lars Bertram; Saadet Mercimek-Mahmutoglu; Darius Ebrahimi-Fakhari; Thomas T Warner; Alexandra Durr; Birgit Assmann; Katja Lohmann; Vladimir Kostic; Christine Klein
Journal:  Mov Disord       Date:  2016-04       Impact factor: 10.338

8.  Neuroacanthocytosis. A clinical, haematological and pathological study of 19 cases.

Authors:  R J Hardie; H W Pullon; A E Harding; J S Owen; M Pires; G L Daniels; Y Imai; V P Misra; R H King; J M Jacobs
Journal:  Brain       Date:  1991-02       Impact factor: 13.501

9.  Chorea, psychosis, acanthocytosis, and prolonged survival associated with ELAC2 mutations.

Authors:  Martin Paucar; Aleksandra Pajak; Christoph Freyer; Åsa Bergendal; Margit Döry; José Miguel Laffita-Mesa; Henrik Stranneheim; Kristina Lagerstedt-Robinson; Irina Savitcheva; Ruth H Walker; Anna Wedell; Anna Wredenberg; Per Svenningsson
Journal:  Neurology       Date:  2018-09-14       Impact factor: 9.910

10.  Neuroacanthocytosis with unusual clinical features: A case report.

Authors:  Hui Zhu; Xue-Min Feng; Teng Zhao; Jing-Yao Liu
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.889

View more
  6 in total

Review 1.  XK-Associated McLeod Syndrome: Nonhematological Manifestations and Relation to VPS13A Disease.

Authors:  Kevin Peikert; Andreas Hermann; Adrian Danek
Journal:  Transfus Med Hemother       Date:  2022-01-25       Impact factor: 3.747

2.  Very Long Time Persistent HyperCKemia as the First Manifestation of McLeod Syndrome: A Case Report.

Authors:  Viviana Torres; Cèlia Painous; Pilar Santacruz; Aurora Sánchez; Cristina Sanz; Josep M Grau-Junyent; Esteban Muñoz
Journal:  Mov Disord Clin Pract       Date:  2022-07-03

3.  Unraveling the Spatiotemporal Distribution of VPS13A in the Mouse Brain.

Authors:  Esther García-García; Nerea Chaparro-Cabanillas; Albert Coll-Manzano; Maria Carreras-Caballé; Albert Giralt; Daniel Del Toro; Jordi Alberch; Mercè Masana; Manuel J Rodríguez
Journal:  Int J Mol Sci       Date:  2021-12-01       Impact factor: 5.923

4.  Changes in Blood Cell Deformability in Chorea-Acanthocytosis and Effects of Treatment With Dasatinib or Lithium.

Authors:  Felix Reichel; Martin Kräter; Kevin Peikert; Hannes Glaß; Philipp Rosendahl; Maik Herbig; Alejandro Rivera Prieto; Alexander Kihm; Giel Bosman; Lars Kaestner; Andreas Hermann; Jochen Guck
Journal:  Front Physiol       Date:  2022-04-04       Impact factor: 4.755

5.  Targeting Lyn Kinase in Chorea-Acanthocytosis: A Translational Treatment Approach in a Rare Disease.

Authors:  Kevin Peikert; Hannes Glaß; Enrica Federti; Alessandro Matte; Lisann Pelzl; Katja Akgün; Tjalf Ziemssen; Rainer Ordemann; Florian Lang; The Network For Translational Research For Neuroacanthocytosis Patients; Lucia De Franceschi; Andreas Hermann
Journal:  J Pers Med       Date:  2021-05-10

6.  Rare Anemias: Are Their Names Just Smoke and Mirrors?

Authors:  Greta Simionato; Richard van Wijk; Stephan Quint; Christian Wagner; Paola Bianchi; Lars Kaestner
Journal:  Front Physiol       Date:  2021-06-10       Impact factor: 4.566

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.